Moreover, this is the first study connecting statin treatment with reduced PLA2G7 activity in prostate cancer cells, and presents a rationale for combining PLA2G7 inhibition with statins in prostate cancer management. This evidence concerns the gene PLA2G7 and Familial prostate cancer.